Sage shares get a bump from a snap­shot of new PhII de­pres­sion da­ta

Sage Ther­a­peu­tics $SAGE has had a lot of suc­cess post­ing in­ter­im snap­shots on the da­ta it’s been gath­er­ing for its pipeline drugs. And the biotech scored an­oth­er surge in its share price to­day with a sliv­er of da­ta from the first stage of its Phase II study of its de­pres­sion drug SAGE-217.

Look­ing at 13 pa­tients – a tiny group for a dis­ease like de­pres­sion – in­ves­ti­ga­tors say that 11 of them demon­strat­ed a min­i­mum 50% re­duc­tion in dis­ease scores. And 8 of them achieved re­mis­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.